Endo Pharmaceuticals has announced the successful clinical results from a Phase II study of axomadol, a drug to treat moderate-to-severe chronic low back pain.

The drug was orally administered at doses ranging from 100mg a day to 300mg a day over a four-week period, with a 12-week maintenance phase.

The randomised, double blind, placebo-controlled and parallel group study included 236 patients and showed a change in average pain intensity from baseline.